Search Results

Filter
  • 1-10 of  1,237 results for ""ABATACEPT""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.

Subjects: Abatacept*/Abatacept*/Abatacept*/therapeutic use ; Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/drug therapy ; Arthritis, Juvenile*/Arthritis, Juvenile*/Arthritis, Juvenile*/blood

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2024 Jun 25; Vol. 26 (1), pp. 125. Date of Electronic Publication: 2024 Jun 25.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.

Subjects: Abatacept*/Abatacept*/Abatacept*/therapeutic use ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/diagnostic imaging

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2022 Feb 16; Vol. 24 (1), pp. 47. Date of Electronic Publication: 2022 Feb 16.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.

  • Authors : Hara R; Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa, 236-0004, Japan. .; Umebayashi H

Subjects: Abatacept/Abatacept/Abatacept/*administration & dosage ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*administration & dosage ; Arthritis, Juvenile/Arthritis, Juvenile/Arthritis, Juvenile/*drug therapy

  • Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2019 Apr 30; Vol. 17 (1), pp. 17. Date of Electronic Publication: 2019 Apr 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.

Subjects: Abatacept/Abatacept/Abatacept/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*epidemiology

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2019 Nov 08; Vol. 21 (1), pp. 228. Date of Electronic Publication: 2019 Nov 08.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

  • Authors : Al-Laith M; Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, London, SE5 9RJ, UK. .; Jasenecova M

Subjects: Abatacept/Abatacept/Abatacept/*administration & dosage ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*administration & dosage ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*prevention & control

  • Source: Trials [Trials] 2019 Jul 15; Vol. 20 (1), pp. 429. Date of Electronic Publication: 2019 Jul 15.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis.

  • Authors : Yokoyama-Kokuryo W; Department of Rheumatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.; Department of Pharmacovigilance, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

Subjects: Abatacept/Abatacept/Abatacept/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*genetics

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2020 Mar 12; Vol. 22 (1), pp. 46. Date of Electronic Publication: 2020 Mar 12.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.

Subjects: Abatacept/Abatacept/Abatacept/*therapeutic use ; Antibodies, Bacterial/Antibodies, Bacterial/Antibodies, Bacterial/*blood ; Arthritis, Juvenile/Arthritis, Juvenile/Arthritis, Juvenile/*drug therapy

  • Source: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2020 Feb 22; Vol. 18 (1), pp. 19. Date of Electronic Publication: 2020 Feb 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101248897 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.

  • Authors : Cagnotto G; Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. .; Department of Rheumatology, Skåne University Hospital, Lund, Sweden. .

Subjects: Abatacept/Abatacept/Abatacept/*therapeutic use ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2020 Jan 22; Vol. 22 (1), pp. 15. Date of Electronic Publication: 2020 Jan 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.

  • Authors : Ozen G; University of Nebraska Medical Center, Omaha, NE, USA.; Pedro S

Subjects: Abatacept/Abatacept/Abatacept/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Biological Factors/Biological Factors/Biological Factors/*therapeutic use

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2019 Jun 07; Vol. 21 (1), pp. 141. Date of Electronic Publication: 2019 Jun 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.

Subjects: Drug Resistance* ; Registries*; Abatacept/Abatacept/Abatacept/*therapeutic use

  • Source: Arthritis research & therapy [Arthritis Res Ther] 2019 Jun 06; Vol. 21 (1), pp. 138. Date of Electronic Publication: 2019 Jun 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium:

Record details

×
  • 1-10 of  1,237 results for ""ABATACEPT""